The global takotsubo syndrome therapeutics industry growth is estimated at a market value of US$ 1.58 Billion by 2023 and is expected to garner a market value of US$ 2.85 Billion by 2033 to expand at a 6.1% value CAGR by 2033. The leading cause of death in both industrialised and developing economies is cardiovascular disease. Cardiovascular disorders include valvular heart disease, congenital heart defects, and cardiac arrest are becoming more common, which is boosting the takotsubo syndrome therapies and cardiac MRI diagnostics sectors.
Due to a rise in the prevalence of heart disease worldwide, North America will hold a disproportionate share of the global market in 2022. The American Heart Association (AHA) claims that heart disease is the main factor in fatalities in North America. Cardiovascular diseases are the major cause of death in China, accounting for 40% of all fatalities, despite significant lifestyle adjustment brought on by rapid urbanisation and environmental shift.
Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16369
The Healthy China 2030 plan, which emphasises the significance of health in China’s innovation and key concepts for achieving this, such as health priority, science and technology innovation, scientific progress, and opening up new markets for advanced echocardiography equipment, particularly cardiovascular ultrasound systems, was approved by the Chinese federal government in 2016. China is therefore anticipated to control industry growth in the ensuing decades.
Key Takeaways from the Market Study:
- Because of rapid advances in cardiovascular care technology, the market is expected to be worth more than US$ 1.5 Billion by 2022.
- The British Heart Foundation estimates that 7.6 million people in the UK will have heart and circulatory diseases by March 2021.
- Heart disease kills approximately 600,000 Americans each year, according to the Centers for Disease Control and Prevention (CDC).
- According to the World Health Organization, approximately 17.9 million people die each year as a result of heart disease.
- Heart and circulatory diseases are responsible for 27% of all deaths in the UK, with approximately 43,000 people dying before the age of 75.
“Future developments will be heavily dependent on further technological advancements, including the use of cell phones, and portable, and handheld testing devices, which will generate a massive potential for growth over the forecast period.” says an analyst at Future Market Insights.
Get The Information You Need By Connecting With Our Analyst Today! https://www.futuremarketinsights.com/ask-question/rep-gb-16369
Key Market Players:
Key players in the takotsubo syndrome therapeutics market are
- Taro Pharmaceutical Industries
- Dva Health & Nutrition GmbH
- Par Formulations Pvt. Ltd.
- Teva Czech Industries S.R.O
- Amneal Pharmaceuticals Pvt. Ltd.
- Bristol-Myers Squibb Company
- Samarth Pharma Pvt. Ltd.
- Cipla Limited
- Ipca Laboratories Ltd.
Recent Development:
- Galderma and Taro Pharmaceutical Industries Ltd. declared a binding agreement in February 2022 for Taro to procure Alchemee, formerly The Proactiv Company (TPC), from Galderma.
- Ipca Laboratories revealed a 35.44% increase in consolidated net profit to Rs. 267.56 crore for the third quarter that concluded December 2020 in February 2021, owing to robust sales in domestic and global markets.
Key Segments Profiled in the Takotsubo Syndrome Therapeutics Industry Survey:
By Diagnosis:
- EKG
- Echocardiography
- Cardiac MRI
- Myocardial Infarction
- Occlusive Myocardial Infarction
- Non-occlusive Myocardial Infarction
- Type II Myocardial Infarction
- Apical Hypertrophic Cardiomyopathy
- Others
By Application:
- Hospitals
- Ambulatory Surgical Centres
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16369
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube